Literature DB >> 31746298

Effectiveness of Stem Cell Therapy in the Treatment of Ovarian Disorders and Female Infertility: A Systematic Review.

Shahin Ahmadian1,2, Mahdi Mahdipour3,4, Mohammad Pazhang2, Sepideh Sheshpari5, Halimeh Mobarak6, Alberto Miranda Bedate7, Reza Rahbarghazi3,8, Mohammad Nouri3,4.   

Abstract

BACKGROUND: Infertility is a major problem worldwide. Various strategies are being used to develop better treatments for infertility and The most trending strategy is the stem cell therapy. In this study, the literature on stem cell therapy for ovarian disorders is summarized with analysis of current developments.
OBJECTIVE: Different published studies on stem cell-based therapy for the treatment of various types of ovarian insufficiency and disorders such as Premature Ovarian Insufficiency (POI) in the affected female population in animal or human clinical studies are systematically reviewed.
METHODS: We monitored five databases, including PubMed, Cochrane, Embase, Scopus, and ProQuest. A comprehensive online search was done using the criteria targeting the application of stem cells in animal models for menopause. Two independent reviewers carefully evaluated titles and abstracts of studies. The stem cell type, source, dosage, route of administration were highlighted in various POI animals models. Non-relevant and review articles were excluded. OUTCOMES: 648 published studies were identified during the initial comprehensive search process from which 41 were selected according to designed criteria. Based on our analysis, stem cells could accelerate ovarian tissues rejuvenation, regulate systemic sex-related hormones levels and eventually increase fertility rate.
CONCLUSION: The evidence suggests that stem cell-based therapies could be considered as an alternative modality to deal with women undergoing POI. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Stem cell therapy; infertility; ovarian disorder; ovarian tissue; premature ovarian insufficiency; transplantation.

Year:  2020        PMID: 31746298     DOI: 10.2174/1574888X14666191119122159

Source DB:  PubMed          Journal:  Curr Stem Cell Res Ther        ISSN: 1574-888X            Impact factor:   3.828


  5 in total

1.  MicroRNA-146 attenuates lipopolysaccharide induced ovarian dysfunction by inhibiting the TLR4/NF- κB signaling pathway.

Authors:  Fengping He; Yanhui Liu; Tang Li; Qiulin Ma; Zhang Yongmei; Peiqing He; Chuanyin Xiong
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

Review 2.  Restoration of Fertility in Patients with Spontaneous Premature Ovarian Insufficiency: New Techniques under the Microscope.

Authors:  Marie Mawet; Sophie Perrier d'Hauterive; Laurie Henry; Iulia Potorac; Frédéric Kridelka; Michelle Nisolle; Axelle Pintiaux
Journal:  J Clin Med       Date:  2021-11-30       Impact factor: 4.241

3.  Intra-ovarian injection of platelet-rich plasma into ovarian tissue promoted rejuvenation in the rat model of premature ovarian insufficiency and restored ovulation rate via angiogenesis modulation.

Authors:  Shahin Ahmadian; Sepideh Sheshpari; Mohammad Pazhang; Alberto Miranda Bedate; Rahim Beheshti; Mehran Mesgari Abbasi; Mohammad Nouri; Reza Rahbarghazi; Mahdi Mahdipour
Journal:  Reprod Biol Endocrinol       Date:  2020-08-05       Impact factor: 5.211

4.  Effects of single and multiple transplantations of human umbilical cord mesenchymal stem cells on the recovery of ovarian function in the treatment of premature ovarian failure in mice.

Authors:  Xiaodan Lv; Chunyi Guan; Ying Li; Xing Su; Lu Zhang; Xueqin Wang; Hong-Fei Xia; Xu Ma
Journal:  J Ovarian Res       Date:  2021-09-15       Impact factor: 4.234

5.  Qilin Pill Exerts Therapeutic Effect on Resection-Induced Premature Ovarian Insufficiency Rats by Inhibiting the MAPK and PI3K-AKT Signaling Pathways.

Authors:  Debao Li; Yuling Jia; Yiwen Hou; Dingshi Chen; Chiyang Zheng; Lifen Chen; Li Zhou; Zuyue Sun
Journal:  Drug Des Devel Ther       Date:  2021-07-30       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.